TY - JOUR
T1 - Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
AU - Chisenga, Caroline C
AU - Bosomprah, Samuel
AU - Chilyabanyama, Obvious N
AU - Alabi, Peter
AU - Simuyandi, Michelo
AU - Mwaba, John
AU - Ng'ombe, Harriet
AU - Laban, Natasha M
AU - Luchen, Charlie C
AU - Chilengi, Roma
N1 - Funding Information: This work was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) grant # TMA2016CDF-1550 and supported by John Hopkins University as well as the Centre for Infectious Disease Research in Zambia (CIDRZ). Funding Information: We thank all the clinic staff at Waya Clinic, the volunteers that worked so tirelessly in making this project a success as well as all the study participants for their willingness to be a part of this program. We also thank the CIDRZ Enteric Disease and Vaccine Research Unit, our drivers Mr. Amon Kanganja and Mr. Martin Lesa, our administrative team Ms. Annie Chikombo and Ms. Joyce Chilekwa for managing all field related logistics. Furthermore, we would also like to thank the research nurses Ms. Fridah Madyabi and Ms. Margaret Chisambi for managing the participants enrolments and blood draws. Finally, we extend our gratitude to Prof. David Sack, Dr. Amanda Debes and the team at Johns Hopkins University for all the various support and interactions on this work. Publisher Copyright: © 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - BACKGROUND: Histo-blood group antigens (HBGAs) which include the ABO and Lewis antigen systems have been known for determining predisposition to infections. For instance, blood group O individuals have a higher risk of severe illness due to V. cholerae compared to those with non-blood group O antigens. We set out to determine the influence that these HBGAs have on oral cholera vaccine immunogenicity and seroconversion in individuals residing within a cholera endemic area in Zambia.METHODOLOGY: We conducted a longitudinal study nested under a clinical trial in which samples from a cohort of 223 adults who were vaccinated with two doses of Shanchol™ and followed up over 4 years were used. We measured serum vibriocidal geometric mean titers (GMTs) at Baseline, Day 28, Months 6, 12, 24, 30, 36 and 48 in response to the vaccine. Saliva obtained at 1 year post vaccination was tested for HBGA phenotypes and secretor status using an enzyme-linked immunosorbent assay (ELISA).RESULTS: Of the 133/223 participants included in the final analysis, the majority were above 34 years old (58%) and of these, 90% were males. Seroconversion rates to V. cholerae O1 Inaba with non-O (23%) and O (30%) blood types were comparable. The same pattern was observed against O1 Ogawa serotype between non-O (25%) and O (35%). This trend continued over the four-year follow-up period. Similarly, no significant differences were observed in seroconversion rates between the non-secretors (26%) and secretors (36%) against V. cholerae O1 Inaba. The same was observed for O1 Ogawa in non-secretors (22%) and the secretors (36%).CONCLUSION: Our results do not support the idea that ABO blood grouping influence vaccine uptake and responses against cholera.
AB - BACKGROUND: Histo-blood group antigens (HBGAs) which include the ABO and Lewis antigen systems have been known for determining predisposition to infections. For instance, blood group O individuals have a higher risk of severe illness due to V. cholerae compared to those with non-blood group O antigens. We set out to determine the influence that these HBGAs have on oral cholera vaccine immunogenicity and seroconversion in individuals residing within a cholera endemic area in Zambia.METHODOLOGY: We conducted a longitudinal study nested under a clinical trial in which samples from a cohort of 223 adults who were vaccinated with two doses of Shanchol™ and followed up over 4 years were used. We measured serum vibriocidal geometric mean titers (GMTs) at Baseline, Day 28, Months 6, 12, 24, 30, 36 and 48 in response to the vaccine. Saliva obtained at 1 year post vaccination was tested for HBGA phenotypes and secretor status using an enzyme-linked immunosorbent assay (ELISA).RESULTS: Of the 133/223 participants included in the final analysis, the majority were above 34 years old (58%) and of these, 90% were males. Seroconversion rates to V. cholerae O1 Inaba with non-O (23%) and O (30%) blood types were comparable. The same pattern was observed against O1 Ogawa serotype between non-O (25%) and O (35%). This trend continued over the four-year follow-up period. Similarly, no significant differences were observed in seroconversion rates between the non-secretors (26%) and secretors (36%) against V. cholerae O1 Inaba. The same was observed for O1 Ogawa in non-secretors (22%) and the secretors (36%).CONCLUSION: Our results do not support the idea that ABO blood grouping influence vaccine uptake and responses against cholera.
KW - ABO Blood-Group System
KW - Administration, Oral
KW - Antibodies, Bacterial
KW - Cholera
KW - Cholera Vaccines
KW - Cholera/epidemiology
KW - Female
KW - Histo-blood group antigens
KW - Humans
KW - Immunogenicity, Vaccine
KW - Longitudinal Studies
KW - Male
KW - Secretory status
KW - Vaccine response, Zambia
KW - Vibrio cholerae O1
KW - Zambia
UR - http://www.scopus.com/inward/record.url?scp=85146743907&partnerID=8YFLogxK
U2 - https://doi.org/10.1186/s12889-023-15051-w
DO - https://doi.org/10.1186/s12889-023-15051-w
M3 - Article
C2 - 36690955
SN - 1471-2458
VL - 23
SP - 152
JO - BMC public health
JF - BMC public health
IS - 1
M1 - 152
ER -